Drug Trial Radar · NCT07937787
A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Nov 20, 2026
Primary completion
Aug 30, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple subcutaneous administration of QLS2406-1. Part A will enroll Chinese adult participants with overweight and obesity, and Part B will enroll participants with obesity.
Conditions
- Overweight and Obesity
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.
PlaceboDrug
Placebo will be administered as a single dose via subcutaneous injection.
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.
PlaceboDrug
Placebo will be administered as a single dose via subcutaneous injection.
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.
PlaceboDrug
Placebo will be administered as a single dose via subcutaneous injection.
QLS2406-1 injectionDrug
Administered subcutaneously
PlaceboDrug
Placebo will be administered as a single dose via subcutaneous injection.
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.
PlaceboDrug
Placebo will be administered as a single dose via subcutaneous injection.
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).
PlaceboDrug
Placebo will be administered by subcutaneous injection once weekly (QW).
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).
PlaceboDrug
Placebo will be administered by subcutaneous injection once weekly (QW).
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).
PlaceboDrug
Placebo will be administered by subcutaneous injection once weekly (QW).
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).
PlaceboDrug
Placebo will be administered by subcutaneous injection once weekly (QW).
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).
PlaceboDrug
Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).
QLS2406-1 injectionDrug
QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).
PlaceboDrug
Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: Baseline to Day 71
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.